The director of the FDA's main drug review office will exit on Jan. 18, according to an email sent to staff. Her departure is ...

Practice of medicine could fundamentally change with these types of therapies,” said CEO Jaideep Dudani, of T cell engagers ...

Nearly 30% of the funding poured into healthcare startups last year, including for biotechs, went to companies leveraging ...

The biotech will stop developing two drugs and lay off nearly three-quarters of its staff after its lead therapy wasn’t as potent in early testing as the company expected.